TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23092143

Group type: EXPERIMENTAL
Intervention: EB (Adper Easy Bond application)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: EB+B (Adper Easy Bond followed by hydrophobic resin coat)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Comparison between EB and EB+B
Number of subjects: 32
Study: 21613575

Group type: COMPARATOR
Intervention: Quercetin (2,000 mg/day)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 8
Study: 20128316

Group type: EXPERIMENTAL
Intervention: Enamel Care dentifrice
Number of subjects: 208

Group type: COMPARATOR
Intervention: Control dentifrice
Number of subjects: 208
Study: 17102716

Group type: EXPERIMENTAL
Intervention: Humorous movies
Number of subjects: 29

Group type: COMPARATOR
Intervention: Neutral movies
Number of subjects: 29
Study: 15607664

Group type: EXPERIMENTAL
Intervention: Left Ventricular Assist Devices (LVADs)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Optimal Medical Management (OMM)
Number of subjects: 129
Study: 11300445

Group type: EXPERIMENTAL
Intervention: Metformin 500 mg twice daily
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 9420539

Group type: EXPERIMENTAL
Intervention: Wax-carbon-laser treatment
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Wax-laser treatment
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Laser alone
Number of subjects: 12

Group type: COMPARATOR
Intervention: Wax control
Number of subjects: 12
Study: 7905033

Group type: EXPERIMENTAL
Intervention: 16-item Negative Symptom Assessment (NSA-16)
Number of subjects: 499

Group type: EXPERIMENTAL
Intervention: NSA-16
Number of subjects: 499
Study: 3318724

Group type: EXPERIMENTAL
Intervention: 12.5 micrograms ethinyloestradiol
Number of subjects: 10
Study: 30144985

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo (mock laser therapy)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control (no laser applied)
Number of subjects: 42
Study: 27716336

Group type: EXPERIMENTAL
Intervention: Adaptive cognitive training (ADAPT-gr) using COGNI-TRAcK with automatic adjustment of task difficulty.
Number of subjects: 28

Group type: COMPARATOR
Intervention: Non-adaptive cognitive training (CONST-gr) using COGNI-TRAcK at constant difficulty levels.
Number of subjects: 28
Study: 24594059

Group type: EXPERIMENTAL
Intervention: Food intake (postprandial conditions)
Number of subjects: 16
Study: 22402954

Group type: EXPERIMENTAL
Intervention: Vitamin C (2 g)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 20696564

Group type: EXPERIMENTAL
Intervention: Ultrasound guidance for epidural placement
Number of subjects: 370

Group type: COMPARATOR
Intervention: Control group (no ultrasound guidance)
Number of subjects: 370
Study: 18487005

Group type: EXPERIMENTAL
Intervention: Standard CPR plus active impedance threshold device (ITD)
Number of subjects: 14742

Group type: COMPARATOR
Intervention: Standard CPR plus sham ITD
Number of subjects: 14742

Group type: EXPERIMENTAL
Intervention: Standard CPR plus active ITD
Number of subjects: 14742
Study: 15969867

Group type: EXPERIMENTAL
Intervention: Olopatadine 0.2%
Number of subjects: 500

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 500
Study: 12795770

Group type: EXPERIMENTAL
Intervention: Alefacept 15 mg IM
Number of subjects: 507

Group type: EXPERIMENTAL
Intervention: Alefacept 10 mg IM
Number of subjects: 507

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 507
Study: 10569747

Group type: EXPERIMENTAL
Intervention: CVD 103-HgR (2 x 10(8) to 8 x 10(8) CFU)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo (killed E. coli K-12)
Number of subjects: 85
Study: 8644628

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 0
Study: 1871078

Group type: EXPERIMENTAL
Intervention: Nurse-assisted self-quit training
Number of subjects: 3161

Group type: EXPERIMENTAL
Intervention: Nurse-assisted recruitment to a group program
Number of subjects: 3161

Group type: EXPERIMENTAL
Intervention: Nurse-assisted combination intervention
Number of subjects: 3161

Group type: COMPARATOR
Intervention: Brief physician advice only
Number of subjects: 3161

Group type: EXPERIMENTAL
Intervention: Nurse-assisted interventions (all types)
Number of subjects: 3161
Study: 6861861

Group type: EXPERIMENTAL
Intervention: Zopiclone 5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zopiclone 10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nitrazepam 5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nitrazepam 10 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30957654

Group type: EXPERIMENTAL
Intervention: Labeling condition (e.g., 'sex offenders', 'murderers')
Number of subjects: 310

Group type: COMPARATOR
Intervention: Neutral condition (e.g., 'people who have committed crimes of a sexual nature')
Number of subjects: 310
Study: 30452511

Group type: EXPERIMENTAL
Intervention: Topical tazarotene gel, 0.1%, applied once every night for 3 months.
Number of subjects: 36

Group type: COMPARATOR
Intervention: Microneedling therapy with a dermaroller (1.5 mm needle length) for a total of 4 sessions over 3 months.
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Patient global assessment score (0-10 scale) for satisfaction at follow-up visits.
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Goodman and Baron quantitative and qualitative scores for acne scar severity.
Number of subjects: 36
Study: 28756871

Group type: COMPARATOR
Intervention: Paclitaxel (80mg/m2 intravenously days 1, 8, and 15 every 4 weeks)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Paclitaxel (80mg/m2 intravenously days 1, 8, and 15) plus reovirus (3×10^10 TCID50/day intravenously on days 1-5)
Number of subjects: 108
Study: 24848975

Group type: EXPERIMENTAL
Intervention: PRGF (one dose)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: PRGF (two doses)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: PRGF plus HA (two doses)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 100
Study: 23592741

Group type: COMPARATOR
Intervention: Healthy Eating diet
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Number of subjects: 120
Study: 21734512

Group type: EXPERIMENTAL
Intervention: 20-hour manualized group cognitive behavior therapy program
Number of subjects: 17

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 17
Study: 19521894

Group type: EXPERIMENTAL
Intervention: Nicotinic acid 16.7 mg
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Nicotinic acid up to 50.1 mg
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Nicotinic acid (all doses)
Number of subjects: 72
Study: 16720057

Group type: EXPERIMENTAL
Intervention: candesartan
Number of subjects: 40

Group type: COMPARATOR
Intervention: amlodipine
Number of subjects: 40
Study: 15084937

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) and sirolimus (Sir)
Number of subjects: 31
Study: 12201348

Group type: EXPERIMENTAL
Intervention: Acetazolamide
Number of subjects: 12
Study: 9150621

Group type: EXPERIMENTAL
Intervention: BMS 180048 150 mg
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: BMS 180048 200 mg
Number of subjects: 216

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 216
Study: 8122735

Group type: EXPERIMENTAL
Intervention: Combined epidural and general anaesthesia and postoperative epidural analgesia (CEGA)
Number of subjects: 50

Group type: COMPARATOR
Intervention: General anaesthesia and postoperative intravenous morphine infusion (GA)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Combined epidural and general anaesthesia (CEGA)
Number of subjects: 50

Group type: COMPARATOR
Intervention: General anaesthesia (GA)
Number of subjects: 50
Study: 2442559

Group type: EXPERIMENTAL
Intervention: lisinopril 5 mg/day
Number of subjects: 129

Group type: COMPARATOR
Intervention: captopril 37.5 mg/day
Number of subjects: 129
Study: 29099420

Group type: COMPARATOR
Intervention: Standard oxygen
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-flow nasal cannula oxygen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Noninvasive ventilation
Number of subjects: 0
Study: 29410934

Group type: EXPERIMENTAL
Intervention: Lurasidone 80mg
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: Lurasidone 160mg
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: Quetiapine XR 600mg
Number of subjects: 488

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: Flexible-dose lurasidone (40 to 160mg/d)
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: Flexible-dose quetiapine XR (200 to 800mg/d)
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 488
Study: 26268736

Group type: EXPERIMENTAL
Intervention: RAMP-DM intervention
Number of subjects: 18188

Group type: COMPARATOR
Intervention: Control group (usual primary care)
Number of subjects: 18188
Study: 24093858

Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation (FES)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 21346065

Group type: EXPERIMENTAL
Intervention: Hesperidin (500 mg once daily for 3 weeks)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 18564150

Group type: EXPERIMENTAL
Intervention: Sildenafil citrate (50 or 100 mg, as needed)
Number of subjects: 209

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 209
Study: 17263129

Group type: EXPERIMENTAL
Intervention: Deferasirox
Number of subjects: 586

Group type: COMPARATOR
Intervention: Deferoxamine
Number of subjects: 586
Study: 14703887

Group type: EXPERIMENTAL
Intervention: Endoscopic haemoclip
Number of subjects: 93

Group type: COMPARATOR
Intervention: Heater probe thermocoagulation plus hypertonic saline‐epinephrine injection
Number of subjects: 93
Study: 10917577

Group type: EXPERIMENTAL
Intervention: Endovascular sclerotherapy (ES)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Surgery + sclerotherapy
Number of subjects: 121

Group type: COMPARATOR
Intervention: Surgery only
Number of subjects: 121
Study: 9010710

Group type: EXPERIMENTAL
Intervention: Moexipril alone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Moexipril with hydrochlorothiazide
Number of subjects: 12

Group type: COMPARATOR
Intervention: Hydrochlorothiazide alone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide with moexipril
Number of subjects: 12
Study: 1313682

Group type: EXPERIMENTAL
Intervention: Itraconazole (200 mg twice daily)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Amphotericin B (0.3 mg/kg daily) plus flucytosine (150 mg/kg daily)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Itraconazole
Number of subjects: 28

Group type: COMPARATOR
Intervention: Amphotericin B plus flucytosine
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid culture positive at 6 weeks
Number of subjects: 28
Study: 4048901

Group type: EXPERIMENTAL
Intervention: TDB (De‐Nol)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 40
Study: 31204320

Group type: EXPERIMENTAL
Intervention: RECIPROC system
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: ProTaper NEXT system
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: ProTaper GOLD system
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: RECIPROC blue system
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (No preparation)
Number of subjects: 75
Study: 30602637

Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Tramadol
Number of subjects: 135
Study: 26967937

Group type: EXPERIMENTAL
Intervention: Subthalamic nucleus deep brain stimulation (STN‐DBS) + optimal drug therapy (ODT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Optimal drug therapy (ODT)
Number of subjects: 0
Study: 25267694

Group type: EXPERIMENTAL
Intervention: Heart rate at 80 bpm and tidal volume at 6 mL/kg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Heart rate at 110 bpm and tidal volume at 6 mL/kg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Heart rate at 80 bpm and tidal volume at 10 mL/kg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Heart rate at 110 bpm and tidal volume at 10 mL/kg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Increasing tidal volume from 6 mL/kg to 10 mL/kg
Number of subjects: 18
Study: 22932705

Group type: EXPERIMENTAL
Intervention: Levosimendan (LEVO)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Furosemide (Controls)
Number of subjects: 33
Study: 20209259

Group type: EXPERIMENTAL
Intervention: Vaginoscopy with physiological saline (0.9% NaCl)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Standard technique with carbon dioxide (CO2)
Number of subjects: 117
Study: 17245607

Group type: EXPERIMENTAL
Intervention: Oral Appliance (OA) therapy
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) therapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 20
Study: 15754377

Group type: EXPERIMENTAL
Intervention: Budesonide 6 mg/d and UDCA 15 mg/kg/d
Number of subjects: 77

Group type: COMPARATOR
Intervention: UDCA 15 mg/kg/d
Number of subjects: 77
Study: 12296610

Group type: EXPERIMENTAL
Intervention: Orlistat
Number of subjects: 531
Study: 10549401

Group type: EXPERIMENTAL
Intervention: Allopurinol (300 mg daily for 4 weeks)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 9
Study: 7885804

Group type: EXPERIMENTAL
Intervention: Sweet (sucrose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Salty (sodium chloride)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sour (citric acid)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bitter (quinine hydrochloride)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 11 possible mixtures of sweet, salty, sour, and bitter
Number of subjects: 0
Study: 2505187

Group type: COMPARATOR
Intervention: L-carnitine (2 g/day) for 6 weeks
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 1277709

Group type: EXPERIMENTAL
Intervention: Bumetanide 1 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Furosemide 40 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Bumetanide 1 mg and Furosemide 40 mg
Number of subjects: 16
Study: 31669455

Group type: EXPERIMENTAL
Intervention: Ultrasonic bone scalpel (BoneScalpel; Misonix, Farmingdale, NY)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Piezoelectric surgical device
Number of subjects: 34

Group type: COMPARATOR
Intervention: Conventional technique (Lindeman burr and reciprocal saw)
Number of subjects: 34
Study: 31324357

Group type: EXPERIMENTAL
Intervention: Acute CAG (<2 hours)
Number of subjects: 496

Group type: COMPARATOR
Intervention: Subacute CAG (<72 hours)
Number of subjects: 496
Study: 27462047

Group type: EXPERIMENTAL
Intervention: Educational lecture delivered by a physician
Number of subjects: 27
Study: 25729878

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 3 g/day
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 23118056

Group type: EXPERIMENTAL
Intervention: Simulated altitude (3000 m) for 10 h/night for 21 nights
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (CON) at 1300 m
Number of subjects: 14
Study: 21199271

Group type: EXPERIMENTAL
Intervention: Low-dosage sulphonylurea (1-mg glimepiride; Amaryl)
Number of subjects: 274

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 274
Study: 19258083

Group type: EXPERIMENTAL
Intervention: Off-pump surgery
Number of subjects: 128

Group type: COMPARATOR
Intervention: On-pump surgery
Number of subjects: 128
Study: 17216477

Group type: EXPERIMENTAL
Intervention: Alendronate + Alfacalcidol (group C)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Alendronate + vitamin D (group B)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Alfacalcidol (group A)
Number of subjects: 90
Study: 15666048

Group type: EXPERIMENTAL
Intervention: Low-volume tumescent liposuction
Number of subjects: 15
Study: 12133129

Group type: EXPERIMENTAL
Intervention: Community alcohol prevention programme including server training in responsible beverage service (RBS) and policy initiatives
Number of subjects: 195

Group type: COMPARATOR
Intervention: Baseline study (1996)
Number of subjects: 195
Study: 9475880

Group type: EXPERIMENTAL
Intervention: Bilateral lower extremity positive pressure cuffs inflated to 45 Torr during exercise (BLPPex)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group with bilateral lower extremity positive pressure cuffs inflated to 45 Torr during recovery (BLPPrec)
Number of subjects: 12
Study: 7890255

Group type: EXPERIMENTAL
Intervention: Outpatient treatment group with incomplete response
Number of subjects: 0

Group type: COMPARATOR
Intervention: Uninfected controls
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Women with chlamydial genital tract infection
Number of subjects: 0
Study: 2254351

Group type: EXPERIMENTAL
Intervention: Prerandomized design
Number of subjects: 0

Group type: COMPARATOR
Intervention: Classic randomization trial
Number of subjects: 0
Study: 28989

Group type: EXPERIMENTAL
Intervention: Triazolam (0.5 mg)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Triazolam (0.25 mg)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120

Group type: COMPARATOR
Intervention: Flurazepam (30 mg)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Flurazepam (15 mg)
Number of subjects: 120
Study: 31722937

Group type: EXPERIMENTAL
Intervention: OEND intervention
Number of subjects: 28

Group type: COMPARATOR
Intervention: Best available standard of care (existing OEND programme)
Number of subjects: 28
Study: 29233291

Group type: EXPERIMENTAL
Intervention: Literary fiction reading intervention over eight weeks (n=11)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group not participating in the intervention (n=10)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Comparison between groups
Number of subjects: 21
Study: 25029703

Group type: EXPERIMENTAL
Intervention: Whey protein hydrolysate (PRO‐CHO)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Carbohydrate drinks (CHO)
Number of subjects: 18
Study: 24130351

Group type: EXPERIMENTAL
Intervention: GLP-1 infusion
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Vitamin C infusion
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Simultaneous infusion of GLP-1 and Vitamin C
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (no infusion)
Number of subjects: 20
Study: 21360201

Group type: EXPERIMENTAL
Intervention: Ice slurry ingestion (1.25 g kg(‐1), -1°C)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Warm fluid ingestion (40°C)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 10
Study: 19961044

Group type: EXPERIMENTAL
Intervention: Single injection lumbar plexus and sciatic nerve blocks
Number of subjects: 44

Group type: COMPARATOR
Intervention: Continuous lumbar plexus and sciatic nerve blocks
Number of subjects: 44
Study: 18046188

Group type: EXPERIMENTAL
Intervention: Carbohydrate (CHO) supplementation (20% maltodextrin at 0.6 g.kg FFM.h)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Flavored placebo (PLA) drink
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Carbohydrate (CHO) supplementation
Number of subjects: 13
Study: 15535402

Group type: EXPERIMENTAL
Intervention: HIV drug resistance testing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matched controls (no resistance testing)
Number of subjects: 0
Study: 11685486

Group type: EXPERIMENTAL
Intervention: 99mTc-colloidal albumin (Nanocoll) at concentrations of 10 MBq/microg and higher, prepared under nitrogen and in vacuum.
Number of subjects: 119
Study: 9989311

Group type: EXPERIMENTAL
Intervention: Enhanced Toilet Training (ETT)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Biofeedback (BF)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Intensive Medical Care (IMC)
Number of subjects: 87
Study: 7816414

Group type: EXPERIMENTAL
Intervention: 0.05% tetrahydrozoline hydrochloride with 0.3% pheniramine maleate
Number of subjects: 10

Group type: COMPARATOR
Intervention: 0.1% tetrahydrozoline hydrochloride
Number of subjects: 10

Group type: COMPARATOR
Intervention: 0.3% chlorpheniramine maleate
Number of subjects: 10
Study: 31411184

Group type: EXPERIMENTAL
Intervention: Double antithrombotic therapy (DT)
Number of subjects: 9931

Group type: COMPARATOR
Intervention: Triple antithrombotic therapy (TT)
Number of subjects: 9931
Study: 28662460

Group type: EXPERIMENTAL
Intervention: Ramelteon SL 0.1mg
Number of subjects: 642

Group type: EXPERIMENTAL
Intervention: Ramelteon SL 0.4mg
Number of subjects: 642

Group type: EXPERIMENTAL
Intervention: Ramelteon SL 0.8mg
Number of subjects: 642

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 642
Study: 25994179

Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg once weekly (QW)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg biweekly (BIW)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg QW/QW
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg BIW/QW
Number of subjects: 171
Study: 22129348

Group type: EXPERIMENTAL
Intervention: Dietary protein at 350 g/kg and lipid at 80 g/kg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Dietary protein at 300 g/kg and lipid at 60 g/kg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Dietary lipid at 80 g/kg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Increase in dietary lipid for each level of dietary protein
Number of subjects: 30
Study: 20598444

Group type: EXPERIMENTAL
Intervention: Abuse-related script
Number of subjects: 75

Group type: COMPARATOR
Intervention: Neutral script
Number of subjects: 75
Study: 19694385

Group type: EXPERIMENTAL
Intervention: Qianlie Beixi Capsule
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control group (compound tablets of zinc and protein)
Number of subjects: 240
Study: 16375950

Group type: EXPERIMENTAL
Intervention: docetaxel‐cisplatin
Number of subjects: 50

Group type: COMPARATOR
Intervention: docetaxel‐carboplatin
Number of subjects: 50
Study: 12720590

Group type: EXPERIMENTAL
Intervention: 30 mg Zn/d for 14 weeks followed by 3 mg Cu/d for 8 weeks
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo supplements
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Both groups (Zn and placebo)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Zn supplementation
Number of subjects: 38